Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, April, 2008 - PR & Med Ed

The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period January to March 2008 inclusive

Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets. To submit an entry for New Accounts, email new_accounts@pmlive.com

CLIENT PRODUCT THERAPEUTIC WINNING AGENCY
Bayer Schering Pharma Rivaroxaban VTE Athena Medical PR
Biomarin Naglazyme Lysosomal Iceberg Medical
Goldshield Macrobid Anti-infective MSA Market Media
GSK Cervarix Vaccine Clew Communications
GSK and Roche Bonviva Osteoporosis Just:: Health PR
Hospira Nipent Oncology Ashley Communications
Johnson and Johnson Nicorette Smoking cessation Virgo Health PR
Leo Pharma Innohep DVT MSA Market Media
Norgine Global New Product n/a Euro RSCG Life UK
OnMedica n/a n/a Life Healthcare Communications
Organon Cezarette, Implanon and Nuvaring Contraception Virgo Health PR
Organon Sugammadex Anaesthesiology Aurora
Pharmion Refludan Haematology Life Leathcare Communications
Takeda Europe New Product n/a Euro RSCG Life UK
UCB (global) Cimzia Gastrointestinal MSA Market Media
UCB (global) Keppra Anti-epileptic MSA Market Media
UCB (Europe) Neupro Parkinson's diesease MSA Market Media

 

2nd September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics